M
Marea Therapeutics
Innovative therapies targeting cardiometabolic diseases using advanced human genetic data
About Marea Therapeutics
Marea is a biotechnology company focused on developing next-generation treatments for cardiometabolic diseases, which are the leading cause of morbidity and mortality worldwide. The company leverages the latest advances in human genetic data to identify, create, and develop novel therapies aimed at addressing the underlying biology of these diseases, rather than just managing symptoms. Marea's therapies are designed to complement existing treatments and provide transformative options for patients who remain at high risk despite current therapies. The company operates in the biopharmaceutical market and serves patients with cardiometabolic conditions, including those at risk for heart attacks even after controlling for traditional risk factors like obesity and elevated LDL cholesterol. Marea's business model involves advancing multiple undisclosed discovery programs that utilize strong human genetics and other validated targets. The company generates revenue through the development and potential commercialization of these novel therapies. Led by a team of experienced scientists and biopharma executives, Marea aims to make a significant impact on the lives of millions of people living with cardiometabolic diseases.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2022
- Headquarters
- South San Francisco, United States
- Employees
- 41
- Open positions
- 1
- Dealroom signal
- 90.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jun 2024 | $143M | $570M | Sofinnova Investments · Alpha Wave Global · Third Rock Ventures · Omega Funds | ↗ |
| SERIES AOther financing | Jan 2024 | $48M | $190M | Third Rock Ventures | ↗ |
Growth signals
Latest recorded traffic for Marea Therapeutics is 7.1K monthly website visits, up 44.9% over the last three months. Marea Therapeutics's team grew 20.6% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
Third Rock Ventures
Sofinnova Investments
Forbion Capital Partners
venBio Partners- PFPerceptive Xontogeny Venture Fund
Alpha Wave GlobalOmega Funds
Surveyor Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Marea Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Marea Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.






